Company Profile

Immtech Pharmaceuticals Inc (AKA: Nextera Therapeutics Inc~ Immtech International Inc ~ )
Profile last edited on: 2/8/2019      CAGE: 418E2      UEI: YMTEYBE24FP1

Business Identifier: Infectious disease therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

One North End Avenue
New York, NY 10282
   (212) 791-2911
Location: Multiple
Congr. District: 10
County: New York

Public Profile

Immtech Pharmaceuticals Inc, formerly dba as Immtech International, Inc. is a biopharmaceutical company focused on the discovery and commercialization of therapeutics for the treatment of patients afflicted with opportunistic infectious diseases, cancer or compromised immune systems such as HIV infected persons. The Company has a pharmaceutical and a biological program for developing drugs. The pharmaceutical program is based on a technology platform for the design of a class of pharmaceutical compounds referred to as dications. The biological program for developing drugs is based on biological proteins that work in conjunction with the body's immune system. These biological proteins are derivatives of C-Reactive Protein (CRP).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $107,000
Project Title: Aromatic Dication Prodrugs for CNS Trypanosomiasis
2001 2 NIH $876,759
Project Title: Novel Prodrugs for Treatment of Opportunistic Infections
2000 1 NIH $107,000
Project Title: Innate Immunity, C-Reactive Protein And Wound Healing
2000 2 NIH $895,489
Project Title: New Broad Spectrum Drugs for Opportunistic Infections
1998 1 NIH $97,292
Project Title: Immunoassays For Pentamidine Like (Dicationic) Drugs

Key People / Management

  Eric L Sorkin -- President

  James L Allen

  David W Boykin

  Samar Makhlouf

  Lawrence A Potempa

  T Stephen Thompson -- former President

Company News

There are no news available.